Guided Therapeutics, Inc. (OTC: GTHP) has developed a biophotonic technology for the early detection of disease that leads to cancer. The technology uses light to detect disease at the cellular level and provide immediate results at the time of the examination, decreasing waiting time and preventing false-positive results. The company’s LuVia Advanced Cervical Scan is being utilized in Canada, Latin America, Europe, Asia and Africa and is under review in the U.S. LuViva is designed to determine the true likelihood of a treatable cervical disease in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result. For more information, visit the company’s website www.guidedinc.com.